ORIC Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

ORIC Pharmaceuticals, a clinical stage oncology company, announced that CFO Dominic Piscitelli will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 7:00 a.m. ET. The presentation will focus on the company's innovative treatment strategies for overcoming resistance in cancer therapies. It will be pre-recorded and accessible via their investor website, with a replay available for 90 days post-event. ORIC's pipeline includes ORIC-533, ORIC-114, and ORIC-944, targeting various cancers and mechanisms of resistance.

SOUTH SAN FRANCISCO and SAN DIEGO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Dominic Piscitelli, chief financial officer, will present a company overview at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022, at 7:00 a.m. ET.

The pre-recorded presentation will be available through the investor section of the company’s website at www.oricpharma.com. A replay will be available for 90 days following the event.

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma, (2) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, and (3) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer. Beyond these three product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on Twitter or LinkedIn.

Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com 
info@oricpharma.com 

FAQ

When is ORIC Pharmaceuticals presenting at the H.C. Wainwright Global Investment Conference?

ORIC Pharmaceuticals will present on May 24, 2022, at 7:00 a.m. ET.

Who is presenting for ORIC Pharmaceuticals at the conference?

Dominic Piscitelli, the Chief Financial Officer, will present for ORIC Pharmaceuticals.

Where can I watch the ORIC Pharmaceuticals presentation?

The pre-recorded presentation will be available on ORIC Pharmaceuticals' investor website.

What are the key products in ORIC Pharmaceuticals' pipeline?

ORIC's key products include ORIC-533, ORIC-114, and ORIC-944, targeting different cancer resistance mechanisms.

How long will the ORIC Pharmaceuticals conference presentation be available for replay?

The replay of the presentation will be available for 90 days following the event.